The long-term goals of this project are to understand the biochemical mechanism of Tat (transactivator) action and to utilize basic knowledge of Tat function to design antagonists of HIV replication. First, to understand Tat function, the investigator proposes to focus on a new human cellular protein of 36 kDa that he has shown to (1) bind tightly to Tat, (2) form a complex with Tat in vitro, and (3) potentiate Tat transactivation when introduced into rodent cells. The author will further characterize this 36 kDa protein, delineate the Tat recognition sequences for binding it, determine cell species and cell type expression, clone its cDNA and study its role in Tat transactivation. Second, in studies to understand Tat uptake, the author will further characterize a 90 kDa cell surface protein that he has found to bind to Tat in vivo and in vitro. He proposes to analyze the role of this 90 kDa protein in Tat cellular uptake by cross-linking studies and Scatchard analysis, to delineate the Tat recognition sequences for binding 90 kDa, and to determine by amino acid sequence analysis whether the 90 kDa is a new protein. If warranted, he will isolate a cDNA clone encoding 90 kDa for further studies. Third, in studies to develop further Tat peptide antagonists of HIV replication, the investigator will utilize the results of mapping studies of Tat recognition sequences for (1) cell uptake, (2) TAR binding, and (3) 36 kDa binding in attempts to design small Tat peptides that will be taken up by cells and block HIV replication. As a long-range goal, analogues of promising Tat peptides will be synthesized by peptide mimetic technology to yield stable and more efficient Tat antagonists. Fourth, to explore the use of Tat peptide sequences to transport foreign polypeptides into cells, the author proposes to analyze the cellular uptake, nuclear transport, and biological function of fusion polypeptides containing Tat """"""""delivery"""""""" sequences. He proposes to first examine the 116 amino acid HIV Rev (regulator of virion protein expression [formerly art/trs]) protein fused to Tat.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI028201-08
Application #
2064298
Study Section
AIDS and Related Research Study Section 3 (ARRC)
Project Start
1989-03-01
Project End
1999-06-30
Budget Start
1996-03-01
Budget End
1999-06-30
Support Year
8
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Saint Louis University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Pandori, M; Craig, H; Moutouh, L et al. (1998) Virological importance of the protease-cleavage site in human immunodeficiency virus type 1 Nef is independent of both intravirion processing and CD4 down-regulation. Virology 251:302-16
Song, C Z (1996) Requirement for phosphorylation of RNA polymerase II C-terminal domain in transcription is both transcript length and promoter dependent. Biochem Biophys Res Commun 229:810-6
Song, C Z; Loewenstein, P M; Green, M (1995) Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat. J Virol 69:2907-11
Yu, L; Zhang, Z; Loewenstein, P M et al. (1995) Molecular cloning and characterization of a cellular protein that interacts with the human immunodeficiency virus type 1 Tat transactivator and encodes a strong transcriptional activation domain. J Virol 69:3007-16
Yu, L; Loewenstein, P M; Zhang, Z et al. (1995) In vitro interaction of the human immunodeficiency virus type 1 Tat transactivator and the general transcription factor TFIIB with the cellular protein TAP. J Virol 69:3017-23
Weeks, B S; Desai, K; Loewenstein, P M et al. (1993) Identification of a novel cell attachment domain in the HIV-1 Tat protein and its 90-kDa cell surface binding protein. J Biol Chem 268:5279-84
Kamine, J; Loewenstein, P; Green, M (1991) Mapping of HIV-1 Tat protein sequences required for binding to Tar RNA. Virology 182:570-7
Desai, K; Loewenstein, P M; Green, M (1991) Isolation of a cellular protein that binds to the human immunodeficiency virus Tat protein and can potentiate transactivation of the viral promoter. Proc Natl Acad Sci U S A 88:8875-9
Green, M; Ishino, M; Loewenstein, P M (1989) Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58:215-23